DelveInsight’s report titled “Frontotemporal Dementia Pipeline Insights 2023” offers extensive information on more than 25+ companies and over 25+ pipeline drugs in the field of Frontotemporal Dementia research. The Frontotemporal Dementia pipeline report encompasses detailed profiles of the pipeline drugs for Frontotemporal Dementia, including information on Frontotemporal Dementia clinical trials and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.
For the Frontotemporal Dementia emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Frontotemporal Dementia pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, Frontotemporal Dementia clinical trial studies conducted for Frontotemporal Dementia, any NDA approvals obtained for Frontotemporal Dementia, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.
To explore more information on the latest breakthroughs in the Frontotemporal Dementia Pipeline treatment landscape of the report, click here @ Frontotemporal Dementia Pipeline Outlook
Key Takeaways from the Frontotemporal Dementia Pipeline Report
- DelveInsight’s Frontotemporal Dementia Pipeline analysis depicts a robust space with 25+ active players working to develop 25+ pipeline treatment therapies.
- The leading Frontotemporal Dementia Companies are working in the market include Prevail Therapeutics, Coya Therapeutics, Alector, Inc., Passage Bio, WaVe life Sciences, CAMP4 Therapeutics, SOLA Biosciences, Denali Therapeutics, Neurimmune, Autifony Therapeutics, and others
- Promising Frontotemporal Dementia Pipeline Therapies in the various stages of development include AL001, TRx0237, memantine hydrochloride, Hydroxypropyl-beta-cyclodextrin, Miglustat, Adrabetadex, Pimavanserin 34 mg, Sebelipase alfa (SBC-102), and others.
- PR006 is being developed as a potentially disease-modifying, single-dose gene therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN). PR006 is designed to slow or stop disease progression in FTD-GRN patients by increasing progranulin levels via delivery of a healthy GRN gene into the central nervous system (CNS). PR006 is administered by injection into the cisterna magna, using the well-studied viral vector AAV9.The U.S. FDA has granted Orphan Drug designation for the treatment of FTD and Fast Track designation for the treatment of FTD-GRN. The European Commission has granted orphan designation for PR006 for the treatment of FTD.PR006 is currently being studied in our PROCLAIM trial, a Phase 1/2 clinical trial of PR006 for the treatment of patients with FTD-GRN.
- AL001 modulates progranulin (PGRN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. We are initially developing AL001 for frontotemporal dementia (FTD) with progranulin mutation (FTD-GRN). The global INFRONT-3 Phase 3 clinical trial is currently enrolling both at-risk and symptomatic participants with FTD-GRN.AL001 is being developed in collaboration with GSK.
Frontotemporal Dementia Overview
Frontotemporal dementia (FTD) or frontotemporal degeneration refers to a group of disorders caused by progressive nerve cell loss in the brain’s frontal lobes (the areas behind your forehead) or its temporal lobes (the regions behind your ears). There are a number of different diseases that cause frontotemporal degeneration.
For further information, refer to the detailed Frontotemporal Dementia Unmet Needs, Frontotemporal Dementia Market Drivers, and Market Barriers, click here for Frontotemporal Dementia Ongoing Clinical Trial Analysis
Frontotemporal Dementia Emerging Drugs Profile
- PR 006: Prevail Therapeutics
- Latozinemab: Alector
- PBFT-02: Passage Bio
- WVE-004: WaVe life Sciences
- EXO-050: Coya Therapeutics
Frontotemporal Dementia Pipeline Therapeutics Assessment
There are approx. 25+ Frontotemporal Dementia companies which are developing the therapies for Frontotemporal Dementia. The Frontotemporal Dementia companies which have their Frontotemporal Dementia drug candidates in the most advanced stage, i.e. phase III include, Deerland Probiotics & Enzymes.
Request a sample and discover the recent advances in Frontotemporal Dementia Ongoing Clinical Trial Analysis and Medications, click here @ Frontotemporal Dementia Treatment Landscape
Frontotemporal Dementia Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the companies in the Frontotemporal Dementia Market include-
Prevail Therapeutics, Coya Therapeutics, Alector, Inc., Passage Bio, WaVe life Sciences, CAMP4 Therapeutics, SOLA Biosciences, Denali Therapeutics, Neurimmune, Autifony Therapeutics, and others
Dive deep into rich insights for drugs for Frontotemporal Dementia Pipeline, click here @ Frontotemporal Dementia Unmet Needs and Analyst Views
Scope of the Frontotemporal Dementia Pipeline Report
- Coverage- Global
- Frontotemporal Dementia Companies- Prevail Therapeutics, Coya Therapeutics, Alector, Inc., Passage Bio, WaVe life Sciences, CAMP4 Therapeutics, SOLA Biosciences, Denali Therapeutics, Neurimmune, Autifony Therapeutics, and others
- Frontotemporal Dementia Pipeline Therapies- AL001, TRx0237, memantine hydrochloride, Hydroxypropyl-beta-cyclodextrin, Miglustat, Adrabetadex, Pimavanserin 34 mg, Sebelipase alfa (SBC-102), and others.
- Frontotemporal Dementia Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Frontotemporal Dementia Mergers and acquisitions, Frontotemporal Dementia Licensing Activities @ Frontotemporal Dementia Emerging Drugs, and Recent Trends
Table of Content
- Introduction
- Frontotemporal Dementia Executive Summary
- Frontotemporal Dementia: Overview
- Frontotemporal Dementia Pipeline Therapeutics
- Frontotemporal Dementia Therapeutic Assessment
- Frontotemporal Dementia– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Latozinemab: Alector
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- PR 006 : Prevail Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- EXO-050: Coya Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Frontotemporal Dementia Key Companies
- Frontotemporal Dementia Key Products
- Frontotemporal Dementia- Unmet Needs
- Frontotemporal Dementia- Market Drivers and Barriers
- Frontotemporal Dementia- Future Perspectives and Conclusion
- Frontotemporal Dementia Analyst Views
- Frontotemporal Dementia Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services